According to TipRanks.com, Antalffy is a 4-star analyst with an average return of 7.9% and a 48.5% success rate. Antalffy covers the Healthcare sector, focusing on stocks such as Axonics Modulation Technologies, Inspire Medical Systems, and Treace Medical Concepts.
Currently, the analyst consensus on Medtronic is a Moderate Buy with an average price target of $128.59, representing a 20.6% upside. In a report issued on January 7, Morgan Stanley also downgraded the stock to Hold with a $120.00 price target.
Based on Medtronic’s latest earnings release for the quarter ending October 31, the company reported a quarterly revenue of $7.85 billion and net profit of $1.31 billion. In comparison, last year the company earned revenue of $7.65 billion and had a net profit of $489 million.
Based on the recent corporate insider activity of 71 insiders, corporate insider sentiment is neutral on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Founded in 1949, Medtronic Plc, a medical technology company, develops, manufactures, distributes, and sells device-based medical therapies and services worldwide. It operates through four segments, including Cardiac and Vascular Group; Minimally Invasive Technologies Group; Restorative Therapies Group; and Diabetes Group. The company is headquartered in Dublin, Ireland.
Read More on MDT:
- Telsey Advisory Thinks Peloton Interactive’s Stock is Going to Recover
- KeyBanc Sticks to Their Buy Rating for Kimbell Royalty Partners (KRP)
- Analyst Provides Guidance for This Canadian Energy Stock
- Needham Thinks Zimmer Biomet Holdings’ Stock is Going to Recover
- DZ BANK AG Maintains Their Buy Rating on Deutsche Bank AG (DB)